Asker Healthcare Group Ab · OMXSTO:ASKER
Asker Healthcare Group Ab — Q1 2026 Earnings Presentation
16 slides from Asker Healthcare Group Ab's earnings presentation, May 6, 2026
Slide 1: Strong start to the year
Q1 INTERIM REPORT JANUARY – MARCH 2026 Strong start to the year Johan Falk, CEO Thomas Moss, CFO 1
Slide 2: Q1 Highlights
Q1 Highlights Q1 2026 • Strong start to the year with good organic growth across all business areas ADJ. EBITA GROWTH • Net sales of SEK 4,521, up 13% of which 5% organic • Adj. EBITA of SEK 442m, up 21%, of which 8% organic 21% of which 8% organic • Adj. EBITA margin strengthened to 9.8% (+0.7 p.p.
Slide 3: Delivering on our financial targets
+18% +68% 9.7% Delivering on our Adj. EBITA R/RK (EBITA/NWC) Adj. EBITA margin growth per year financial targets LTM 2025/2026 TARGET >15% TARGET >50% TARGET (medium term) >10% 2.15x 0.39 Net Debt/EBITDA* SEK/share Proposed dividend TARGET <2.5x TARGET >30% of last year’s net profit after tax 3 *Adj
Slide 4: Continuing to deliver stable and profitable total EBITA growth quarter over quarter
Continuing to deliver stable and profitable total EBITA growth quarter over quarter Adj. EBITA R121) SEKm 1,672 >15% CAGR 317 Q1 Q1 Q1 Q1 Q1 Q1 Q1 2020 2021 2022 2023 2024 2025 2026 4 1) EBITA excl. items affecting comparability and estimated Covid-19 effect ’20-‘22.
Slide 5: Financial performance – Group
Financial performance – Group Solid performance and good organic growth across the group Amounts in Q1 2026 Q1 2025 LTM Jan - Dec January - March 2026 SEKm 2025/2026 2025 Adj. EBITA growth Net sales 4,521 3,995 17,312 16,787 30% 17% 25% Adj. EBITA 442 364 1,672 1,594 21% 20% -4% Adj. EBITA 9.8% 9.1%
Slide 6: Business Area North
Business Area North Business in North continues to perform well with good organic growth Amounts in Q1 2026 Q1 2025 LTM Jan - Dec January - March 2026 SEKm 2025/2026 2025 • Adj. EBITA growth 5% Net sales 1,354 1,263 5,301 5,210 ⎯ Organic growth of 4% ⎯ Acquired growth of 2% Adj. EBITA 186 177 690 68
Slide 7: Business Area West
Business Area West Strong growth in West with contributions from scale effects Amounts in Q1 2026 Q1 2025 LTM Jan - Dec January - March 2026 SEKm 2025/2026 2025 • Adj. EBITA growth 32% Net sales 2,254 2,008 8,789 8,543 ⎯ Organic growth of 15% ⎯ Acquired growth of 23% Adj. EBITA 213 161 810 757 ⎯ Exc
Slide 8: Business Area Central
Business Area Central Significant sales and EBITA growth from across the region Amounts in Q1 2026 Q1 2025 LTM Jan - Dec January - March 2026 SEKm 2025/2026 2025 • Adj. EBITA growth 47% Net sales 913 725 3,222 3,034 ⎯ Organic growth of 13% ⎯ Acquired growth of 39% Adj. EBITA 80 54 284 259 ⎯ Exchange
Slide 9: R/RK remains strong
R/RK remains strong R/RK • R/RK amounted to 67.7% (66.5) 100% • Continued efficient working capital utilisation across all business area 80% 60% 40% 20% 0% Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 R/RK (EBITA/NWC) Asker target >50% 9
Slide 10: Robust cash flow with good visibility on M&A plan and future outflows
Robust cash flow with good visibility on M&A plan and future outflows • Cash flow from operating activities SEK 419m (109) in Q1 Jan-Dec Amounts in SEKm Q1 2026 Q1 2025 2025 • Strong overall top and bottom-line growth combined with continued working capital efficiency Cash flow from operating activi
Slide 11: Stable leverage below target level, allowing for continued acquisitions
Stable leverage below target level, allowing for continued acquisitions Net debt/EBITDA* development Amounts in SEKm 31 March 2026 31 March 2025 3x Net debt 3,871 2,585 EBITDA* 1,804 1,521 Net debt/EBITDA* 2.15 1.70 Adj. Net debt/EBITDA** 2.25 1.70 2x • Leverage remains at stable levels – 2.25x in Q
Slide 12: Strengthening our position through M&A
Strengthening our position through M&A Business Annual sales, Month Acquisition Area SEKm* • Acquisitions of Van Heek Medical and Q1 ‘26 March RMS Medical Devices Completed in Apr West 170 GHC/MPF completed in Q1, adding SEK 650m January GHC/MPF Completed in Feb Central 300 in annual sales December
Slide 13: Explore an acquisition
Explore an acquisition • GHC/MPF mainly serves the German homecare market with incontinence and urology products but also sells to clinics and pharmacies • Strong and growing position in its niche, with a portfolio of high-quality private label products that is attractive to GHC and MPF many of our
Slide 14: Q1 in summary
Q1 in summary • Strong quarter with solid performance across the group from both established companies and newer acquisitions • Good organic growth, +5% of net sales growth and +8% of adj. EBITA growth • Two new acquisitions signed in the quarter, strengthening our position within direct to patient
Slide 15: Q&A
Q&A
Slide 16: Financial calendar
Financial calendar • Annual General Meeting 7 May 2026 • Q2 report 2026 21 July 2026 • Q3 report 2026 4 Nov 2026 We are health in progress Additional information Thomas Moss, CFO and Head of IR • Improve patient outcome • Reduce total cost of care Tel: +46 70 219 79 05 • Ensure a fair and sustainabl
Asker Healthcare Group — Q1 2026 Earnings Presentation on 6ix